DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Netherton syndrome — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNetherton syndrome maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for netherton syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
interleukin 4 receptor (IL4R) — IL4R is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1IAR · 2.3 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Three patients with Netherton syndrome in Malaysia were treated with secukinumab and showed variable outcomes. The authors note that only about eight patients globally had been reported on secukinumab for this condition before their observation, with good outcomes in those earlier reports. No response rates, survival figures, or quantitative efficacy data are given for the three Malaysian patients.
A 2022 study used CRISPR/Cas9 to create a mouse model of Netherton syndrome by targeting exon 3 of the mouse Spink5 gene. Sequencing confirmed a 22-bp deletion. Histology showed complete detachment of the stratum corneum from the underlying granular layer and absence of LEKTI in skin from homozygous knockout mice. The authors present this as a tool for future gene correction and skin barrier studies, not as a treatment.
A 2024 case report describes a 6-year-old patient with Netherton syndrome managed with dupilumab for three years, described as successful. No quantitative outcomes such as severity scores, infection rates, or laboratory values are reported. The authors summarise the existing literature on dupilumab for Netherton syndrome and discuss its potential role in pathogenesis.
A 2021 review of 43 infants with Netherton syndrome seen over 38 years at a Paris referral centre found that half suffered dehydration with high blood sodium, two-thirds were underweight, a quarter had cow’s milk allergy, and a quarter had diarrhoea. Two-thirds had skin infections; 42% developed septicaemia. Four babies died in the first nine months, usually with infection, and three of those also had very high sodium. Diagnosis was confirmed by absence of LEKTI in skin biopsy and by SPINK5 gene mutations. Babies with one particular mutation were more severely affected. The authors recommend careful hygiene, nearly double fluid requirements, and increased protein and calories, and call for expert multidisciplinary care in specialist units. What remains missing are controlled trials of any drug for Netherton syndrome, validated outcome measures for paediatric patients, and stratification by genotype to predict which patients might benefit from which biologic.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical and Experimental Dermatology · 2023 · 3 citations
Secukinumab for Netherton syndrome: a Malaysian experience
AbstractWe described three patients with Netherton syndrome in Malaysia treated with secukinumab with variable outcomes. To date, there have only been reports of about eight patients being treated with secukinumab globally with this condition, with good outcomes. We hope our observation will add to the existing global pool of information about Netherton syndrome treated with secukinumab.
European Journal of Dermatology · 2022 · 2 citations
Establishment of a mouse model of Netherton syndrome based on CRISPR/Cas9 technology
AbstractBackground: Netherton syndrome is a rare but severe autosomal recessive disorder with dominant impaired skin barrier function, caused by mutations in the SPINK5 (serine protease inhibitor Kazal-type 5) gene, which encodes LEKTI (lymphoepithelial Kazal-type-related inhibitor). Objectives: To establish a murine model of Netherton syndrome based on CRISPR/Cas9 gene editing technology. Materials & Methods: Spink5-sgRNA was designed to target exon 3 of the mouse Spink5 gene. Cas9 mRNA and sgRNA were microinjected into the zygotes of C57BL/6J mice. Spink5 homozygous knockout mice were born from a heterozygous intercross, and the phenotype of these mice was compared with wild-type regarding gross morphology, histopathology and immunofluorescent detection of LEKTI. Results: Following microinjection of zygotes using the CRISPR/Cas9 system, sequencing demonstrated a 22-bp deletion at exon 3 of the mouse Spink5 gene. Histological investigation revealed complete detachment of the stratum corneum from the underlying granular layer and an absence of LEKTI in skin from Spink5 homozygous knockout mice. Conclusion: The 22-bp deleted Spink5 transgenic mouse model demonstrates the clinical phenotype and genotype of human Netherton syndrome, representing a useful tool for future gene correction and skin barrier/inflammation studies.
Asian journal of pediatric dermatology. · 2024 · 1 citations · open access
Long-term Dupilumab Therapy in a Pediatric Patient with Netherton Syndrome: A Case Report and Review of the Literature
AbstractAbstract Netherton syndrome (NS) is an inherited ichthyosis without targeted therapies, and current treatment remains largely symptomatic. Herein, we report the case of a 6-year-old patient with NS successfully managed with dupilumab for 3 years. The literature regarding dupilumab treatment in this patient population is summarized, and the potential role of dupilumab in altering the pathogenesis of NS is discussed.
British Journal of Dermatology · 2021 · 0 citations · open access
Lessons from 43 infants with Netherton syndrome
AbstractNetherton syndrome is a genetic condition affecting about five people per million. It appears at or soon after birth with skin rash, unusual hair, allergy and abnormal immunity. Affected babies may become very ill, but severity varies and most dermatologists see only a few cases. Doctors from a specialist referral centre in Paris reviewed cases seen over 38 years to try to put together some guidelines. Of 43 babies with Netherton syndrome, half suffered dehydration with high sodium levels in their blood. Two-thirds were underweight, a quarter had cow’s milk allergy and a quarter had diarrhoea. Infections were common: two-thirds had skin infections, others had lung, catheter, kidney or heart infections and 42% developed septicaemia (blood infection). Some unusual hormone problems occurred. Four babies died in the first 9 months, usually with infection but three also had very high sodium levels. The typical rash and hair changes may not be apparent early on. A suspected diagnosis of Netherton syndrome may be confirmed by absence of a key component called LEKTI in a skin biopsy (where a small section of the skin is removed for testing) and by changes (mutations) in the SPINK5 gene in blood. Babies with one particular mutation were more severely affected. Because of the risk of serious infection, careful hygiene measures are advised especially during the first months of life. Excessive protein and fluid are lost through damaged skin and bowel so babies with Netherton syndrome need almost double quantities of fluid and increased amounts of protein and calories. The authors call for expert multidisciplinary care in specialist units. Linked Article: Bellon et al. Br J Dermatol 2021; 184:532–537.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
